-
1
Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
Published 2025-02-01Subjects: “…upadacitinib…”
Get full text
Article -
2
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
Published 2025-02-01Subjects: Get full text
Article